Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

Also called NCT01849497

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 149 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01849497
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01849497. Randomized; no masking; primary purpose treatment. Start 2013-04-18 (actual); primary completion 2013-09-02 (actual). Results posted on 2015-10-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Condition
Primary Hypercholesterolemia
Condition
Mixed Dyslipidemia
Intervention (Biological)
Evolocumab Pre-filled Syringe
Intervention (Biological)
Evolocumab AI/pen
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01849497
Content hash
9fb086458bfa3ea5fc762f11ff1965edd4ba3481285b82490109dd272bf43431